** Shares of Argent BioPharma RGT.AX rise as much as 52.9% to A$0.260, their biggest intraday pct gain since Oct 1, 2024
** The clinical-stage biopharma co completes $4.5 mln capital raise at $0.40 per share
** Issue price represents a premium of 276.5%, compared with stock's last closing price of A$0.17
** Says placement will help advance co's drug development pipeline, with focus on clinical studies for CannEpil - a seizure-control treatment for refractory epilepsy and cerebral palsy
** Stock hits its highest level since Dec 2
** About 231,485 shares change hands, 13.2 times the 30-day average volume of 17,562
** Stock fell 64.2% in 2024
(Reporting by Manasi Dasa Sundeep in Bengaluru)
((Manasi.DasaSundeep@ThomsonReuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。